Tumor-associated antigens and biomarkers in cancer and immune therapy (Q36844959)

16 August 2017

1 reference

title

Tumor-associated antigens and biomarkers in cancer and immune therapy (English)

1 reference

16 August 2017

0 references

1 reference

Uriel M Malyankar

1

1 reference

16 August 2017

publication date

1 May 2007

1 reference

International Reviews of Immunology

16 August 2017

published in

1 reference

16 August 2017

volume

26

1 reference

16 August 2017

issue

3-4

1 reference

16 August 2017

page(s)

223-247

1 reference

Cancer biomarkers--an invitation to the table

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

21 January 2018

Common cancer biomarkers

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Sample collection, processing, and storage for large-scale studies: biorepositories to support cancer research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Bias as a threat to the validity of cancer molecular-marker research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Gene expression informatics--it's all in your mine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Microarray-based DNA methylation profiling: technology and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

The use and analysis of microarray data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Minimum information about a microarray experiment (MIAME)-toward standards for microarray data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Mining expressed sequence tags identifies cancer markers of clinical interest

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Molecular portraits and the family tree of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Forensic genetics and ethical, legal and social implications beyond the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Chemosensitivity prediction by transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Genomic signatures to guide the use of chemotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Oncomirs - microRNAs with a role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Proteomics: from gel based to gel free.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

The sentinel within: exploiting the immune system for cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Use of proteomic patterns in serum to identify ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

The blood peptidome: a higher dimension of information content for cancer biomarker discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Characterization of the low molecular weight human serum proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Analysis of albumin-associated peptides and proteins from ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

A human protein atlas for normal and cancer tissues based on antibody proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Pathway analysis of kidney cancer using proteomics and metabolic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Tumor antigens as surrogate markers and targets for therapy and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Tumor-associated antigen arrays for the serological diagnosis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Autoantibody signatures in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Computational methods for prediction of T-cell epitopes--a framework for modelling, testing, and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Malignant melanoma: genetics and therapeutics in the genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Peptide vaccine trials for melanoma: preclinical background and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Therapeutic vaccines for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Rational approaches to human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Biomarkers for the development of cancer vaccines: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

The tumor-draining lymph node as an immune-privileged site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

The US Food and Drug Administration perspective on cancer biomarker development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180701402496

10.1080/08830180701402496

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference